# Maravai LifeSciences Holdings share price today (Maravai LifeSciences Holdings, Inc., MRVI)

> Maravai LifeSciences Holdings, Inc.'s results are improving, and its P/E is near the top of its own history, higher than 99% of past readings. MRVI · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/mrvi

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $6.98 (+143.2% in a year)
- P/E: 48.2× (higher than 99% of the last 2.1 years)
- Revenue (Jun 2026): $51.4 M (+8.5% on a year ago)
- Profit (Jun 2026): −$12.4 M
- Operating margin: −29.4% (+44.0 points on a year ago)
- ROE: −35%, FY25
- ROIC: −10.2%, against a 7.7% cost of capital: −17.9 points
- Profit that came in as cash: 225%, last 2 years

The main question: results are strong, and the P/E is higher than 99% of its own history. ## What is the Maravai LifeSciences Holdings share price today? Maravai LifeSciences Holdings, Inc.'s share price was $6.98 at the close on 5 November 2026. It has been rising for 29 weeks. That is 31.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $9, and at that close it sat 71% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 5.9 years the share price moved −76% while the S&P 500 moved +102%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Maravai LifeSciences Holdings pay? Maravai LifeSciences Holdings, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Maravai LifeSciences Holdings on? Maravai LifeSciences Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Maravai LifeSciences Holdings profitable? Maravai LifeSciences Holdings, Inc. posted a net loss of $12.4 M in the Jun 2026 quarter. The full FY25 year was a loss of $131 M. That loss is 24.1% of the quarter's revenue. The same quarter a year earlier lost $39.6 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Maravai LifeSciences Holdings make, and is it growing? Maravai LifeSciences Holdings, Inc. reported $51.4 M of revenue in the Jun 2026 quarter, +8.5% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown −30.6% a year on average. The last full year, FY25, came in at $186 M. The last four reported quarters add to $209 M. FY25 revenue was $186 M, −28.3% on the year before. Recent pace: the last four quarters grew −0.6% on average, against −30.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −5.0%, against −12.8% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Maravai LifeSciences Holdings keep? Maravai LifeSciences Holdings, Inc.'s operating margin was −29.4% in the Jun 2026 quarter, 44.0 percentage points higher than the same quarter a year ago. Across 5 years it has been between −67.6% and 68.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +44.0 percentage points on the year while gross margin changed +23.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Maravai LifeSciences Holdings' profit turning into cash? Over the last 2 years, 225% of Maravai LifeSciences Holdings, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 its operations used $57.6 M of cash, against −$131 M of profit. After $13.1 M of spending on assets, free cash was −$70.7 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Maravai LifeSciences Holdings' cash go? Maravai LifeSciences Holdings, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $108 M on assets over the last 3 years. Averaged over those years that is 19.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $108 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Maravai LifeSciences Holdings' P/E ratio, and how does it compare with its own history? Maravai LifeSciences Holdings, Inc.'s P/E is 48.2×, about the highest it has ever been. Its usual P/E (the middle reading) is 16.2×, over 2.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Maravai LifeSciences Holdings business getting better or worse? Maravai LifeSciences Holdings, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Maravai LifeSciences Holdings earn on its capital? Maravai LifeSciences Holdings, Inc. earned a ROE of −35% in FY25. Its return on capital used (ROIC) is 17.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −70.4% net margin and 0.24× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −70.4% net margin × 0.24× asset turnover × 2.07× leverage (assets divided by equity) ≈ −35.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −10.2% − 7.7% = −17.9 percentage points. The 7.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −10.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −21.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Maravai LifeSciences Holdings have too much debt? Maravai LifeSciences Holdings, Inc. has total debt of $218 M against shareholder equity of $356 M as of Jun 2026, so its debt is 0.61× its equity. Year by year, that ratio went from 1.05 in FY21 to 0.98 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Maravai LifeSciences Holdings shareholding pattern? 12.6% of Maravai LifeSciences Holdings, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 4.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Maravai LifeSciences Holdings from balance-sheet trouble? For Maravai LifeSciences Holdings, Inc., the Z-score is 1.39. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.39 is inside the danger zone, so the balance sheet is a real risk. ## How does Maravai LifeSciences Holdings rank in its industry? There is no score against its industry: Maravai LifeSciences Holdings, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Maravai LifeSciences Holdings compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Maravai LifeSciences Holdings in size? Maravai LifeSciences Holdings is the 81st largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Harmony Biosciences Holdings, Inc., Vir Biotechnology, Inc. and Sarepta Therapeutics, Inc. Just below it: Stoke Therapeutics, Inc., Zenas BioPharma, Inc. and Agios Pharmaceuticals, Inc. ### Biotechnology companies close in size

1. [Harmony Biosciences Holdings, Inc.](https://www.sectoralpha.in/us/stocks/hrmy) $1.9 billion
2. [Vir Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/vir) $1.9 billion
3. [Sarepta Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/srpt) $1.9 billion
4. Maravai LifeSciences Holdings, Inc. $1.8 billion
5. [Stoke Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/stok) $1.7 billion
6. [Zenas BioPharma, Inc.](https://www.sectoralpha.in/us/stocks/zbio) $1.7 billion
7. [Agios Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/agio) $1.7 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Fortrea Holdings Inc.](https://www.sectoralpha.in/us/stocks/ftre) $2 billion · Biotechnology
2. [Sarepta Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/srpt) $2 billion · Biotechnology
3. Maravai LifeSciences Holdings, Inc. $2 billion
4. [RLX Technology Inc.](https://www.sectoralpha.in/us/stocks/rlx) $2 billion · Tobacco
5. [Harmony Biosciences Holdings, Inc.](https://www.sectoralpha.in/us/stocks/hrmy) $2 billion · Biotechnology

## What else do people ask about Maravai LifeSciences Holdings? ### What were Maravai LifeSciences Holdings's latest quarterly results? Maravai LifeSciences Holdings, Inc. reported revenue of $51.4 M and a net loss of $12.4 M for the Jun 2026 quarter. Earnings per share were −$0.08. The operating margin was −29.4%, 44.0 percentage points higher than a year earlier (as of 5 November 2026). ### What is Maravai LifeSciences Holdings's market cap? Maravai LifeSciences Holdings, Inc.'s market capitalisation is $1.8 B at a stock price of $6.98. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Maravai LifeSciences Holdings performing? Maravai LifeSciences Holdings, Inc.'s share price has been rising for 29 weeks. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Maravai LifeSciences Holdings's stock price go up? This page does not forecast Maravai LifeSciences Holdings, Inc.'s stock price. What it shows instead: the stock price is $6.98, and it has been rising for 29 weeks. Its P/E of 48.2× is higher than 99% of its own last 2 years (as of 5 November 2026). ### Is Maravai LifeSciences Holdings's profit real cash? Yes, over the last 2 years, 225% of Maravai LifeSciences Holdings, Inc.'s reported profit came in as cash from operations. The latest year was lower at 44%, so the trend is worth watching. In FY25, operating cash was −$57.6 M against reported profit of −$131 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 5 November 2026). ### Where is Maravai LifeSciences Holdings in its business cycle? Maravai LifeSciences Holdings, Inc.'s FY25 operating margin was −67.6%, against a 5-year range of −67.6% to 68.0%: the low end of its own range, which is often where recoveries start. The latest quarter was −29.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Maravai LifeSciences Holdings story? The main question: results are strong, and the P/E is higher than 99% of its own history. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Maravai LifeSciences Holdings a stock worth studying right now? What the numbers show: Maravai LifeSciences Holdings, Inc.'s results are improving, and its P/E is near the top of its own history, higher than 99% of past readings. The main open question: whether earnings grow enough to match the multiple. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.